3 completed, 2 active not recruiting, 1 unknown. 4 Phase 3, 1 Phase 1, 1 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 4 | Completed 2, Active not recruiting 1, Unknown 1 |
| Phase 1 | 1 | Completed 1 |
| Phase 4 | 1 | Active not recruiting 1 |
Follow Professor Francois Venter: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Randomised, Phase 3 Non-inferiority Study of DOR/3TC/TDF Compared to DTG/TAF/FTC in Participants Infected With HIV-1 Starting First-line Antiretroviral Therapy Delstrigo, KOCITAF - HIV-1-infection | Phase 3 | Active not recruiting | Professor Francois Venter | 600 | 2023-11-08 | 2025-04-02 |
| Utilizing Private Pharmacies to Initiate High-risk Young Individuals on PrEP in South Africa Tenofovir disoproxil fumarate + lamivudine/emtricitabine (TDF+3TC /FTC) - HIV Infection | Phase 4 | Active not recruiting | Professor Francois Venter | 1900 | 2023-05-19 | 2025-06-05 |
| ADORE: Efficacy of DORavirine in Adults Living With HIV Experiencing Virological Failure on First-line Efavirenz-based Antiretroviral Therapy With NNRTI Resistance Doravirine/Lamivudine/Tenofovir - HIV-1-infection | Phase 3 | Unknown | Professor Francois Venter | 25 | 2021-02-09 | 2022-06-07 |
| DORA: A Doravirine-based First-line Antiretroviral Therapy for Women of Reproductive Potential Living With HIV Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate - HIV-1-infection | Phase 3 | Completed | Professor Francois Venter | 133 | 2021-01-04 | 2023-08-03 |
| The Effect of Rifampicin on the Pharmacokinetics of Intracellular Tenofovir-diphosphate and Tenofovir When Coadministered With Tenofovir Alafenamide Fumarate During the Maintenance Phase of Tuberculosis Treatment in TB/HIV-1 Coinfected Participants Phase 1: Tenofovir disoproxil fumarate/Emtricitabine/Efavirenz coadministered with Rifampicin/Isoniazid, Phase 2: Tenofovir alafenamide/Lamivudine/Efavirenz coadministered with Rifampicin/Isoniazid, Phase 3: Tenofovir disoproxil fumarate/Emtricitabine/Efavirenz - HIV-1-infection, Tuberculosis | Phase 1 | Completed | Professor Francois Venter | 18 | 2019-12-05 | 2022-06-07 |
| ADVANCE Study of DTG + TAF + FTC vs DTG + TDF + FTC and EFV + TDF+FTC in First-line Antiretroviral Therapy Dolutegravir, Tenofovir Alafenamide, Truvada - HIV-1 Infection | Phase 3 | Completed | Professor Francois Venter | 1110 | 2017-01-16 | 2023-02-08 |
HIV Infections (1) · Tuberculosis (1) · Weight Gain (1)
Efavirenz, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination (2) · doravirine (2) · Emtricitabine (1) · Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination (1) · Lamivudine (1) · Racivir (1) · Tablets (1) · Tenofovir (1) · dolutegravir (1) · efavirenz (1) · emtricitabine tenofovir alafenamide (1) · tenofovir alafenamide (1)
South Africa (6)
Simiso Sokhela, MBBCh (2) · Fanscois Venter, PhD in Medicine (1) · Simiso Sokhela (1) · Willem Daniel Francois Venter, FCP (SA) (1)
PMID 31339677, PMID 33010240, PMID 33262331, PMID 33625064, PMID 37098852, PMID 38978403, PMID 41328799, PMID 42536019